Optomed Plc
Annual Report 2019

ABOUT US

Optomed in brief

Optomed is a Finnish medical technology company and a leading manufacturer of handheld fundus cameras globally.

We combine handheld fundus cameras with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye diseases such as rapidly increasing diabetic retinopathy.

CEO REVIEW

We are accelerating our growth in new markets

“The year 2019 was an important year for Optomed with several highlights, including a very successful market expansion of our handheld fundus camera, Aurora, opening of several complimentary sales channels for our products and over-subscribed initial public offering (IPO) on Nasdaq Helsinki’s main list. We now have the right products as well as the funds needed to grow and expand our business to new markets and customer segments globally.”

Seppo Kopsala
CEO

Read more

Key figures 2019

Net sales

15.0

EUR, million

Gross margin

66.4

%

Adjusted EBITDA

-0.2

EUR, million

Equity ratio

57.2

%

BUSINESS MODEL

Complete solutions for eye screening

In our business, we combine handheld fundus cameras with software and artificial intelligence. We are expanding into new markets through various sales channels. Due to outsourced equipment manufacturing our business model is scalable.

Read more
OPERATING ENVIRONMENT

Optomed is a leading player in a growing market

Optomed operates in the global fundus camera market. The market is estimated to be around 535 million USD (in 2018) and the annual growth rate is around 4 percent. The handheld fundus camera market is expected to grow much faster than the overall market, around 11 percent annually.

Read more